Important changes for patients from September 1. A new list of reimbursed drugs will come into force. 147 products or new indications were added to the list. Will be reimbursed, among others one of the most expensive drugs in the world – Zolgensma, used in gene therapy for spinal muscular atrophy (SMA).
- From September 1, a new list of reimbursed drugs will apply
- He found, among others the drug Zolgensma, used in gene therapy for spinal muscular atrophy, considered the most expensive drug in the world
- The list also includes drugs used in the treatment of squamous cell carcinoma of the head and neck organs, acute myeloid leukemia and multi-drug resistant pulmonary tuberculosis
- Reimbursement guidelines for some diabetes medications are changing
- More information on interesting information can be found on the Onet homepage
New list of reimbursed drugs
The latest announcement on the list of reimbursed drugs, foodstuffs for particular nutritional uses and medical devices was published in the Official Journal of the Minister of Health.
Updating the reimbursement list enables the introduction of new products with proven effectiveness and generic drugs – equivalents of original drugs containing the same active substance. Thanks to the reimbursement, patients can buy cheaper medicines, foodstuffs for particular nutritional uses and medical devices. The reimbursed products can be purchased at a pharmacy that has signed an agreement with the National Health Fund.
Due to the positive decisions on total reimbursement, 147 products or new indications were added to the list.
Among the new indications, in addition to the drug Zolgensma, used in the gene therapy of spinal muscular atrophy (SMA), there are also i.a. Keytruda, a medicine used to treat squamous cell cancer of the head and neck organs; Mylotarg – used in the treatment of patients with acute myeloid leukemia and Dovprela – used in the treatment of multi-drug resistant pulmonary tuberculosis or pulmonary tuberculosis with extended resistance.
Important changes for diabetics
According to the new reimbursement list, there are, inter alia, extension of the scope of funding for five active substances already included in the reimbursement list. Oral antidiabetic drugs – phlosines – canagliflozinum (Invokana drug) and dapagliflozinum (Forxiga drug) will be reimbursed in the changed indication, which should translate into increased availability among patients.
The biggest reductions will apply to the following products: Seebri Breezhaler (glycopyrronii bromidum, inhalation powder in hard capsule, 44 µg, 30 capsules plus an inhaler) – by PLN 20,79; Aquacel AG + Extra (emplastri collagenosa, reinforced dressing in hydrofiber technology with the addition of silver 20 × 30 cm, dressing, 600 cm square, 1 item) – by PLN 9,35 in the case of free payment and by PLN 7,87 in the case of the level of payment of 30 percent. and Aquacel Ag Foam (emplastri antimicrobiotica, adhesive foam dressing in hydrofiber technology with the addition of silver 25 × 30 cm, dressing, 750 cm square, 1 item) – by PLN 6,15 for the free level of payment and by PLN 4,30 in in the case of the payment level of 30 percent.
You can find a package of tests checking the basic parameters important in the prevention of diabetes in Medonet Market.
What will travel the most?
The largest increase will apply to the Novo-Helisen Depot product (house dust mite allergen extracts, concentration 3–5000 TU / ml or 5000 PNU / ml, 2 vials, 4,5 ml each) – it will cost 452,70 PLN more.
For 123 products, official selling prices were reduced (from PLN 0,01 to PLN 5). For 808,51 products, official selling prices were increased (from PLN 30 to PLN 0,08). For 799,20 items, the patient’s surcharge will drop (from PLN 270 to PLN 0,01) in the announcement. For 20,79 items, the patient’s surcharge will increase (from PLN 188 to PLN 0,01) in the announcement. Gross retail prices for 452,70 products will decrease (from PLN 235 to PLN 0,01). Gross retail prices for 37,47 products will increase (from PLN 87 to PLN 0,02).
Due to the receipt of applications for the shortening of the validity period of reimbursement decisions or the expiry of the validity period of reimbursement decisions or the refusal of reimbursement for the next period, the notice will not include 92 products or indications listed in the previous notice.
Author: Agata Zbieg.